Claim Ledger
75% answered
Did management answer the analysts?
12 analyst questions audited, 2 evaded or deflected.
View Claim Ledger →Chandan Healthcare Ltd — Q3 FY26
Chandan Healthcare delivered a solid Q3 FY26 with revenue of ₹65.77 Cr (+20% YoY) and EBITDA of ₹12.61 Cr (+39% YoY), driven by 34% growth in B2C diagnostics.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Chandan Healthcare delivered a solid Q3 FY26 with revenue of ₹65.77 Cr (+20% YoY) and EBITDA of ₹12.61 Cr (+39% YoY), driven by 34% growth in B2C diagnostics. EBITDA margin expanded 263 bps to 19.17%, despite a one-time gratuity provision of ₹2.2 Cr. PAT grew 8% to ₹4.54 Cr. The company is aggressively expanding: 6 comprehensive centers and 18 labs opened YTD, with 9 more labs launching next month. A landmark 10-year government contract for radiology services in Punjab and Assam (₹55 Cr annual revenue) will commence over the next six months. Management guided for significantly higher growth in FY27, with EBITDA margins expected to improve to 30-35% as new centers mature. Key risk: rapid expansion could strain working capital and employee costs, which rose to 18% of revenue this quarter.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Employee Cost Inflation
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
B2C Diagnostic Sales Growth
34%
+34% YoY
B2C diagnostic sales grew 34% YoY, the major contributor to overall revenue growth.
Comprehensive Centers Opened YTD
6
+6 vs prior year
Six new comprehensive diagnostic centers started this financial year, offering pathology and radiology under one roof.
Franchisee Locations Enrolled
100
+100 vs prior year
Franchisee network expanded to over 100 locations, with results expected from Q4.
Government Contract Annual Revenue
₹55 Cr
New contract
10-year contract for radiology services in 8 Punjab districts and 1 Assam railway hospital, worth ₹55 Cr per year.
Fast read
Guidance and risk preview
Management indicated that FY27 revenue growth will be 'much much higher' than 30%, driven by new centers and the government contract.
Employee costs rose to 18% of revenue due to expansion-related hiring and one-time gratuity provisioning; may pressure margins if revenue ramp-up l...
View Risks →